Stay updated on Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial
Sign up to get notified when there's something new on the Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial page.

Latest updates to the Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial page
- CheckyesterdayChange DetectedThe page's revision label updated from v3.5.3 to v3.5.4, indicating an update to the site's frontend template used for displaying the study details. There are no visible changes to study information or page layout described by the provided data.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedA new revision tag v3.5.3 was added and the previous v3.5.0 tag was removed, indicating an administrative update to the study record's revision history. This update does not affect study data, eligibility criteria, or user-facing content.SummaryDifference0.0%

- Check59 days agoChange DetectedNapoli, Italy, 80131 was updated to Naples, Italy, 80131. The page revision was updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check73 days agoChange DetectedThe website revision was updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check82 days agoChange DetectedLayout/UI updates were observed on the Study Details page. Core study information such as eligibility criteria, outcomes, and locations remains unchanged.SummaryDifference0.0%

- Check96 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 in the page footer, representing a minor version bump with no other visible changes observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial page.